COXFA4L2 and papillary renal cell carcinoma: Like SHMT2, overexpressed NDUFA4L2 also was associated with worse OS in patients with renal clear cell carcinoma and renal papillary cell carcinoma (P < 0.05, respectively) (Fig. 7).